Serious adverse events · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
Adverse events · people who received phacoemulsification
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · induction of remission in Crohn's disease
It is very uncertain whether enteral nutrition changes adverse events compared with corticosteroids (very low certainty).
1 finding from 1 review
Adverse events · Patients with a pathological diagnosis of central giant cell granuloma (CGCG) of the jaws
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Serious adverse events 48 weeks · adults and children with chronic asthma
It is very uncertain whether increased changes serious adverse events 48 weeks compared with stable doses of inhaled corticosteroids (very low certainty).
1 finding from 1 review
Non‐serious adverse events 43 weeks · adults and children with chronic asthma
It is very uncertain whether increased changes non‐serious adverse events 43 weeks compared with stable doses of inhaled corticosteroids (very low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
1 finding from 1 review
Adverse events · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: local · people with eczema
1 finding from 1 review
Adverse events (all) · adults with asthma well controlled on LABA and ICS
Stopping LABA showed no clear difference in adverse events (all) compared with continuing use of LABA+ICS (moderate certainty).
1 finding from 1 review
Adverse events (all) · adults with asthma not well controlled on ICS
Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in adverse events (all) compared with long‐acting beta2‐agonists (LABA) add‐on (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · induction of remission in Crohn's disease
It is very uncertain whether enteral nutrition changes withdrawal due to adverse events compared with corticosteroids (very low certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Methotrexate showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Interferon beta‐1a showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · Adults with plantar heel pain¹
1 finding from 1 review
Intervention not reported
Serious adverse events · children with chronic asthma
The intervention showed no clear difference in serious adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · children with chronic asthma
The intervention showed no clear difference in serious adverse events (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with chronic asthma
LABA + ICS showed no clear difference in serious adverse events compared with LTRA + ICS (moderate certainty).
1 finding from 1 review
Systemic adverse events at · people with eczema
1 finding from 1 review
Serious adverse events ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review